# 1 Effectiveness of *Wolbachia*-infected mosquito deployments in reducing the incidence of dengue

# 2 and other *Aedes*-borne diseases in Niterói, Brazil: a quasi-experimental study

- 3
- 4 Sofia B. Pinto<sup>1</sup>, Thais I. S. Riback<sup>1</sup>, Gabriel Sylvestre<sup>1</sup>, Guilherme Costa<sup>1</sup>, Julia Peixoto<sup>1</sup>, Fernando B. S.
- 5 Dias<sup>1,2</sup>, Stephanie K. Tanamas<sup>3</sup>, Cameron P. Simmons<sup>3,4</sup>, Suzanne M. Dufault<sup>5</sup>, Peter A. Ryan<sup>3</sup>, Scott L.
- 6 O'Neill<sup>3</sup>, Frederico C. Muzzi<sup>3</sup>, Simon Kutcher<sup>3</sup>, Jacqui Montgomery<sup>3</sup>, Benjamin R. Green<sup>3</sup>, Ruth
- 7 Smithyman<sup>3</sup>, Ana Eppinghaus<sup>6</sup>, Valeria Saraceni<sup>7</sup>, Betina Durovni<sup>1,8</sup><sup>^</sup>, Katherine L. Anders<sup>3</sup><sup>\*</sup>, Luciano
- 8 A. Moreira<sup>1,9^\*</sup>
- 9
- 10 <sup>1</sup> World Mosquito Program, Fiocruz, Rio de Janeiro, Brazil
- 11 <sup>2</sup> Gabinete da Presidência, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- <sup>3</sup> World Mosquito Program, Institute of Vector Borne Disease, Monash University, Clayton, 3800,
   Australia
- <sup>4</sup>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5,
   Ho Chi Minh City, Vietnam
- <sup>5</sup> Division of Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, USA
- <sup>6</sup>City Health Secretariat, Niteroi, Brazil
- 18 <sup>7</sup> City Health Secretariat, Rio de Janeiro, Brazil
- 19 <sup>8</sup>Centre for Strategic Studies, Fiocruz, Rio de Janeiro, Brazil
- 20 <sup>9</sup>Instituto Rene Rachou, Fiocruz, Belo Horizonte, Brazil
- 21
- 22 <sup>^</sup> These authors contributed equally to this work
- 23 \* Correspondence: <u>luciano.moreira@worldmosquito.org</u>; <u>katie.anders@worldmosquito.org</u>
- 24

# 25 Abstract

- 26 Background: The introduction of the bacterium Wolbachia (wMel strain) into Aedes aegypti
- 27 mosquitoes reduces their capacity to transmit dengue and other arboviruses. Evidence of a
- reduction in dengue case incidence following field releases of wMel-infected Ae. aegypti has been
- 29 reported previously from a cluster randomised controlled trial in Indonesia, and quasi-experimental
- 30 studies in Indonesia and northern Australia.
- 31 *Methods:* Following pilot releases in 2015 2016 and a period of intensive community engagement,
- 32 deployments of adult *w*Mel-infected *Ae. aegypti* mosquitoes were conducted in Niterói, Brazil during
- 33 2017 2019. Deployments were phased across four release zones, with a total area of 83 km<sup>2</sup> and a
- residential population of approximately 373,000. A quasi-experimental design was used to evaluate
- 35 the effectiveness of *w*Mel deployments in reducing dengue, chikungunya and Zika incidence. An
- 36 untreated control zone was pre-defined, which was comparable to the intervention area in historical
- 37 dengue trends. The *w*Mel intervention effect was estimated by controlled interrupted time series
- 38 analysis of monthly dengue, chikungunya and Zika case notifications to the public health surveillance
- 39 system before, during and after releases, from release zones and the control zone.
- 40 *Results:* Three years after commencement of releases, *w*Mel introgression into local *Ae. aegypti*
- 41 populations was heterogeneous throughout Niterói, reaching a high prevalence (>80%) in the
- 42 earliest release zone, and more moderate levels (prevalence 40 -70%) elsewhere. Despite this spatial
- 43 heterogeneity in entomological outcomes, the *w*Mel intervention was associated with a 69%
- reduction in dengue incidence (95% confidence interval 54%, 79%), a 56% reduction in chikungunya
- 45 incidence (95%Cl 16%, 77%) and a 37% reduction in Zika incidence (95%Cl 1%, 60%), in the aggregate
- 46 release area compared with the pre-defined control area. This significant intervention effect on
- 47 dengue was replicated across all four release zones, and in three of four zones for chikungunya,
- 48 though not in individual release zones for Zika.

49 Conclusions: We demonstrate that wMel Wolbachia can be successfully introgressed into Ae. aegypti 50 populations in a large and complex urban setting, and that a significant public health benefit from 51 reduced incidence of Aedes-borne disease accrues even where the prevalence of wMel in local 52 mosquito populations is moderate and spatially heterogeneous. These findings are consistent with 53 the results of randomised and non-randomised field trials in Indonesia and northern Australia, and 54 are supportive of the Wolbachia biocontrol method as a multivalent intervention against dengue, 55 chikungunya and Zika.

# 57 Introduction

- 58 Dengue is a mosquito-borne disease transmitted primarily by the *Aedes aegypti* mosquito, which has
- 59 increased globally in both case burden and geographic footprint over the past 50 years.
- 60 Approximately 40% of the world's population are at risk of dengue transmission, with an estimated
- 400 million infections per year resulting in 50 100 million clinical cases and 3.6 million
- 62 hospitalisations.<sup>1,2</sup> The economic cost to health systems and communities has been estimated at
- 63 \$8.9 billion per annum.<sup>3</sup> In Brazil, more than 1.5 million dengue cases and 782 deaths were reported
- nationally in 2019, with in excess of 1300 cases per 100,000 population in the worst affected
- 65 Central-West region. In the same year 132,000 cases of chikungunya also transmitted by Ae.
- 66 *aegypti* mosquitoes were reported, including 92 deaths.

67 Current strategies for dengue control are limited to efforts to suppress immature and adult

- 68 mosquito numbers, through spraying of insecticides and community campaigns to reduce breeding
- 69 sites. Even where considerable resources are invested in these activities, sustained suppression of
- 70 mosquito densities has been elusive, and seasonal outbreaks continue to occur.<sup>4,5</sup> There is a well-
- 71 recognised need for new, affordable and effective tools for control of dengue and other Aedes-borne
- 72 arboviruses, including chikungunya and Zika.<sup>4,6</sup>

73 Stable introduction of the common insect bacterium Wolbachia (wMel strain) into Ae. aegypti has 74 been shown in the laboratory to result in Ae. aegypti having reduced transmission potential for 75 dengue and other Aedes-borne arboviruses including chikungunya, Zika, Yellow Fever and Mayaro 76 virus.<sup>7-14</sup> Female Ae. aegypti mosquitoes infected with wMel transmit the bacterium with high 77 fidelity to their offspring via infected eggs and wMel manipulates mosquito reproductive outcomes via a process called cytoplasmic incompatibility, which favours introgression of wMel into a wild-78 type population.<sup>13</sup> Accumulating evidence from field sites in Australia and Indonesia has 79 80 demonstrated large reductions in dengue incidence in areas where short-term releases of wMel-81 infected mosquitoes have resulted in introgression and sustained high prevalence of wMel in local Ae. aegypti populations.<sup>15-17</sup> A recently completed cluster randomised trial of wMel Wolbachia 82 deployments in Yogyakarta, Indonesia, conclusively demonstrated the efficacy of the method, with a 83 84 77% reduction in dengue incidence in Wolbachia-treated neighbourhoods compared to untreated 85 areas.<sup>18</sup> The Yogyakarta CRT included chikungunya and Zika as secondary endpoints, but insufficient 86 cases were detected to permit an evaluation of efficacy against these arboviruses. Acquiring field 87 evidence for the effectiveness of Wolbachia in reducing transmission of these arboviruses is a 88 priority, as is the accumulation of real-world evidence for public health impact from large-scale

implementations of *w*Mel-infected *Ae. aegypti* in the complex urban environments common
throughout dengue-endemic areas.

91 Pilot releases of *Wolbachia*-infected mosquitoes started in 2014 in Rio de Janeiro and in 2015 in

- 92 Niterói, Brazil, and achieved successful establishment of *Wolbachia* throughout the two small pilot
- 93 site communities, each with a population of 2500-2800 people.<sup>19,20</sup> In 2017 Niterói became the first
- site in Brazil to move to scaled deployments across a large urban area. The intervention involved a
- 95 phased approach including engagement with and acceptance by the community, communication
- 96 strategies to ensure the communities were informed and supportive, releases of Wolbachia-infected
- 97 *Ae. aegypti* mosquitoes, and monitoring of the levels of *Wolbachia* in *Ae. aegypti* in the field.
- 98 We report here the entomological and epidemiological outcomes of a large-scale non-randomised
- 99 deployment of *Wolbachia*-infected *Ae. aegypti* mosquitoes in the Brazilian city of Niterói, for the
- 100 control of dengue and other *Aedes*-borne diseases. The impact of *Wolbachia* deployment on
- 101 dengue, chikungunya and Zika incidence was evaluated via a quasi-experimental study, using
- 102 controlled interrupted time series analysis of routine notifiable disease surveillance data, in
- 103 accordance with a pre-defined protocol.<sup>21</sup>
- 104
- 105

### 106 Methods

### 107 Study setting

- 108 Niterói, a municipality of the state of Rio de Janeiro is situated in the Guanabara Bay across from Rio
- de Janeiro city (22°52′58″S 43°06′14″W). According to the last national census in 2010 it had a
- population of 484,918 living in an area of 135 km<sup>2</sup>. The city is divided into 7 health districts for
- administrative planning. For the evaluation of the impact of Wolbachia mosquito deployments,
- 112 Niteroi was divided into four release zones and 1 control zone, which are aligned with
- 113 neighbourhood administrative boundaries (Figure 1). Table 1 shows the baseline characteristics and
- 114 release summary of each zone.



115

116 **Figure 1: Study site map** showing the municipality of Niterói, comprising four zones in which

117 releases of *w*Mel-infected *Aedes aegypti* have been undertaken and one pre-defined parallel

118 untreated control zone. Neighbourhood boundaries are shown in white. The inset shows the

119 location of Niterói within the state of Rio de Janeiro, Brazil.

120

121 **Table 1:** Baseline characteristics and summary of *w*Mel releases and monitoring by zone

Zone	Population	Total area km <sup>2</sup>	Release area km <sup>2</sup>	# Release periods*	Estimated mosquitoes released	# of BG traps (& after reduction)	BG trap density per km2 (& after reduction)	Month BG traps first installed
Release zone 1 <sup>^</sup>	23,747	9.2	3.5	2	2,638,847	138 (49)	39 (14)	01/2017
Release zone 2	68,695	50.6	18.9	2	12,836,261	302 (229)	16 (12)	07/2017
Release zone 3	178,891	12.6	9.4	3	12,609,558	169	18	12/2017
Release zone 4	101,784	10.9	8.1	1	6,169,702	140	17	10/2019
Control zone	111,801	51.25	-	I	-			

122 \* number of separate periods of releases (see Figure 2, open circles indicate months when

123 Wolbachia releases took place in any part of that zone). In zone 3, the second release period began

immediately after the first, in March 2018, and so appears continuous in Figure 2. ^Release zone 1

includes the Jurujuba neighbourhood where pilot releases were conducted in 2015-16,<sup>20</sup> for all

126 metrics except 'Estimated mosquitoes released' which includes only the expanded releases in zone 1

127 beginning in February 2017; the month that BG traps were first installed in zone 1 also excludes the

128 pilot release period. Note: release area comprises all urban or constructed areas in the zone, but

129 excludes green non-constructed areas, which are less favourable habitats for *Ae. aegypti*. The

- 130 number and density of BG traps was reduced in parts of zone 1 and zone 2 in order to reduce
- 131 monitoring costs, once releases were completed and neighbourhood-level wMel prevalence was
- 132 >60% in 3 consecutive monitoring events measured at least 4 weeks after the conclusion of releases.
- 133 Maps of release and BG trap locations are included in the supplementary material as Figures S3 and
- 134 S4.
- 135

### 136 Ethics and approvals

- 137 Approval to release Wolbachia-carrying Ae. aegypti mosquitoes into urban areas was obtained from
- three Brazilian governmental bodies: the National Agency of Sanitary Surveillance (ANVISA); the

139 Ministry of Agriculture, Livestock and Supply (MAPA); and the Brazilian Institute of Environment and

- 140 Renewable Natural Resources (IBAMA), which issued a Temporary Special Registry (Registro Especial
- 141 Temporário (RET), nr. 0551716178/2017). Ethical approval was also obtained from the National
- 142 Commission for Research Ethics (CONEP CAAE 59175616.2.0000.0008).

143

### 144 Community engagement

WMP Brazil's Communication and Engagement (C&E) strategy was developed prior to mosquito
 releases, following a thorough analysis of geographical, social, political, economic and cultural factors
 in the proposed release areas as previously described.<sup>22</sup>

In Niterói the C&E plan was focused on three key areas: public schools, primary health care units and social leadership, due to their reach and influence within the release area, including into vulnerable communities. Community Reference Groups (CRGs) were also created, to serve as advisory committees populated by representatives of the planned release areas, to inform the activities of WMP Brazil. This group was also responsible for providing feedback on all communication materials and C&E strategies that were proposed throughout the WMP's activities in their areas.

154 Prior to the release of wMel-infected mosquitoes in each area, a survey of awareness and acceptance 155 of the method was conducted by an independent company. In order to reach a wide range of people 156 living and working in the release areas, time-location sampling was used to survey passers-by in busy 157 public locations in each neighbourhood. Respondents (n= 3485 in total) were 18 years and over, and 158 lived or worked in the neighbourhood where the survey was conducted. The questionnaire was 159 developed with the CRG, and included questions on awareness ("Have you heard about the Wolbachia 160 method?"), understanding after explanation of the method ("Do you understand that this method 161 replaces the population of Aedes aegypti mosquitoes with Aedes aegypti mosquitoes carrying

Wolbachia, which have a reduced capacity to transmit dengue, Zika and chikungunya?") and
acceptance of the proposed wMel releases ("Do you agree with Fiocruz releasing these mosquitoes
with Wolbachia here in your neighbourhood?").

165

#### 166 Mosquito production

The Rio *w*Mel-infected *Ae. aegypti* line described in Garcia et al 2019<sup>23</sup> was used for releases. The 167 wMel-infected lines were maintained in controlled laboratory conditions, in 900 cm<sup>2</sup> mesh-sided 168 169 rearing cages. Each cage contained 2500-2750 adults, and was fed using donated non-transfusional 170 usable human blood (agreement FIOCRUZ/ Hemominas OF.GPO/CCO-Nr224/16), once per week for 171 two to three gonotrophic cycles. As a quality assurance procedure each blood bag was tested for 172 dengue, Zika, chikungunya, Mayaro and yellow fever viruses, as described previously<sup>9,11,24</sup>. Two 173 separate colonies were maintained, a broodstock (kept in Belo Horizonte) and a release-production 174 colony (kept in Rio de Janeiro). Male Ae. aegypti adults (from F0-F1 field collected material) were 175 introduced into the broodstock cages at a rate of 10-20% every 5 generations. This outcrossing 176 frequency was sufficient to maintain kdr resistant genotypes within the broodstock colony throughout 177 its maintenance (see supplementary methods and Figure S1). Material from the broodstock colony 178 was then transferred to the release-production colony where it was amplified through 2 amplifications 179 without the addition of field collected males. A minimum sample of 168 mosquitoes from the release-180 production colony was screened for wMel infection on a weekly basis, using quantitative polymerase 181 chain reaction (qPCR) as described below. wMel prevalence was 100% in all but three weekly screening 182 events, and was never below 97%. Quantitative analysis of wMel in these samples detected a fairly constant wsp:rps17 copy number between 4 to 6 (Figure S2). 183

184 From April 2017 until April 2018 immature stages for adult releases were reared at a density of 185 approximately 1.0 larvae/ml and fed a diet of ground Tetramin Tropical Flakes (Tetra Holding [US] Inc. 186 Germany, Product number 77101). From May 2018, immature stages for adult releases were reared at a density of approximately 2.75 larvae/ml and fed a diet of fish food: liver powder: yeast extract 187 188 (4:3:1). We found no detrimental effects on outcomes, including development time, size, egg output 189 or wMel density, with increases in larval density up to 2.75/ml. In both rearing regimes, when 190 approximately 10-30% of larvae had pupated, the larvae/pupae were sieved and between 180-220 191 larvae/pupae were placed in a release device. The release device was a cylindrical PVC crystal tube 192 approximately 28 mm in diameter and 250 mm in length, covered with a fixed mesh on one side and a removable mesh on the other side. Adults were allowed to emerge for 5-6 days and were 193 194 maintained on a 10% sugar solution for 12-36 hours prior to releases. We estimated that the releases

were slightly male biased with an average female:male ratio within the devices of 3:4. The releasedevices were then stacked, sugar-free into boxes for transport to the release site.

197

# 198 Wolbachia deployments

199 Mosquito deployments took place over a release area of 40 km<sup>2</sup> during a period of 35 months 200 (February 2017 - December 2019). Adult wMel-infected mosquitoes were released weekly from a 201 moving vehicle. In Zones 1 - 3 mosquito release points were initially determined using a 50 meter grid 202 overlaid on the release areas, with one release point per grid square. In Zone 4 the density of release 203 points was adjusted for the residential population in each neighbourhood, with the aim of releasing a 204 cumulative total of 100 mosquitoes per resident (average distance between release points on a 205 regular grid was 41 meters). In all areas, the initial release points determined on the grids were then 206 distributed to the nearest vehicle-accessible road for vehicle releases (Figure S3). Releases were 207 staged throughout the urban constructed areas in each release zone. Green non-constructed areas 208 were excluded from releases as they provide less favourable habitats for Ae. aegupti and had few or 209 no human residents. Initial release periods were 10-16 weeks duration, with subsequent re-releases conducted in local areas where wMel prevalence was <40% in 3 consecutive monitoring events as 210 211 measured at least 4 weeks after the conclusion of releases. This 40% threshold was based on previous estimates of the unstable equilibrium point for *w*Mel, above which invasion can occur.<sup>25</sup> This resulted 212 213 in re-releases being conducted in approximately 30% of the initial release areas. Most areas of Zones 214 1 and 2 had two periods of releases, Zone 3 had three periods of releases and Zone 4 only 1 release 215 period.

216

# 217 Wolbachia monitoring

218 Mosquitoes were collected weekly during and after releases using a network of BG Sentinel traps 219 (Biogents AG, Regensburg, Germany, Product number NR10030) at an average density of 16 BG 220 traps/km<sup>2</sup> throughout release areas (Figure S4). Once wMel prevalence was detected at >60% in 3 221 consecutive monitoring events measured at least 4 weeks after the conclusion of releases, trap 222 numbers were reduced to 50% within a neighbourhood (Figure S4). Mosquitoes were sent to the 223 laboratory for sorting, morphological identification and counting. The number of mosquitoes caught 224 in each BG trap was recorded by species, sex, and in total. Mosquito samples were stored in 70% 225 ethanol until screening for wMel-strain Wolbachia. Screening was performed weekly until week 226 ending 8 April 2018 and fortnightly thereafter.

#### 227

# 228 Wolbachia molecular detection

A maximum of 10 adult Ae. aegypti per BG trap per collection were screened for the presence of wMel 229 230 using either quantitative polymerase chain reaction (qPCR), or a colorimetric loop-mediated 231 isothermal amplification (LAMP) assay. Taqman qPCR was performed on a Roche LightCycler 480 as described previously.<sup>16,26</sup> Briefly, the qPCR cycling program consisted of a denaturation at 95°C for 5 232 min followed by 40 cycles of PCR (denaturation at 95 °C for 10 min, annealing at 60 °C for 30 sec, and 233 234 extension at 72 °C for 1 sec with single acquisition) followed by a cooling down step at 40°C for 30 sec. 235 LAMP reactions were performed in a Bio-Rad C1000 96-well PCR thermocycler with a 30min incubation at 65°C as previously described.<sup>16</sup> Individual reactions consisted of 2X WarmStartR 236 Colorimetric LAMP Master Mix (New England BioLabs, Cat# M1800S), primers and 1 µL of target DNA 237 238 from a 50 $\mu$ l single mosquito squash buffer extraction assay, in a total reaction volume of 17  $\mu$ L. An 239 individual mosquito was scored as positive for Wolbachia if the Cp (crossing point) value in qPCR was 240 below 28, or if the well in the LAMP assay was yellow upon visual inspection. Equivocal results were 241 counted as negative. Details of primer and probe nucleotide sequences are included in the 242 supplementary materials.

243

### 244 Epidemiological data

Data on dengue and chikungunya cases notified to the Brazilian national disease surveillance system (SINAN) were used to evaluate the epidemiological impact of *Wolbachia* releases. Reporting of both diseases is mandatory in Brazil. Dengue notification data for Niterói is available from SINAN since 2007 and chikungunya since 2015. Notified dengue and chikungunya cases reported to SINAN are predominantly suspected cases based on a clinical case definition.<sup>27</sup>

Between 2007 - 2014, approximately 15% of notified dengue cases had supportive laboratory test results, usually from IgM serology. Since the Zika epidemic in Brazil in 2015, laboratory confirmation of dengue has relied on PCR only due to cross-reactive serological responses, and only one dengue case notified in 2015 - 2020 included laboratory confirmation. For chikungunya, 24% of cases notified in 2015 - 2020 had supportive IgM serology results. For the purpose of this analysis, we include all notified dengue and chikungunya cases (suspected and laboratory confirmed).

Anonymized disaggregate data on notified suspected and laboratory-confirmed dengue, severe dengue, chikungunya and Zika cases were obtained from the SINAN system through the Health Secretariat of Niterói, for the period from January 2007 (January 2015 for chikungunya and Zika) to

June 2020. Population data by neighbourhood of residence from the Brazilian 2010 census (IBGE) was
used to estimate the population in each *Wolbachia* release zone.

261

### 262 Measurement of epidemiological impact

263 The wMel intervention effect was estimated using controlled interrupted time series analysis 264 performed separately for each release zone compared with the pre-defined control area, and for the aggregate release area compared with the control area, as described in a published study protocol.<sup>21</sup> 265 266 The primary analysis included data from January 2007 (dengue) or January 2015 (chikungunya and 267 Zika), until June 2020, encompassing 8-37 months of post-intervention observations. For zone-level 268 analyses, negative binomial regression was used to model monthly dengue, chikungunya and Zika case 269 counts in the intervention and control areas, with an offset for population size. Seasonal variability in 270 disease incidence was controlled using flexible cubic splines with knots placed at 6-monthly intervals. 271 For the primary analysis, a binary 'group' variable indicated the study arm (intervention or control). A 272 binary 'treatment' variable distinguished the pre-intervention period and the post-intervention 273 period. The zone-level post-intervention period was defined as four weeks after wMel releases had 274 commenced throughout the whole zone; the corresponding post-intervention period was also applied 275 to the control area for each zone-level analysis. The intervention effect was estimated from the 276 interaction between the 'group' and 'treatment' variables, which allows explicitly for a level change in 277 the outcome (dengue/chikungunya/Zika case incidence) in both intervention and control areas in the 278 post-intervention period. Robust standard errors were used to account for autocorrelation and 279 heteroskedasticity. A mixed-effects negative binomial regression was used to model monthly dengue, chikungunya or Zika case counts in the aggregate release area compared with the control area, with 280 281 an offset for population size and controlling for seasonal variability in incidence using flexible cubic 282 splines with knots placed at 6-monthly intervals. Clustering of dengue/chikungunya/Zika cases by 283 release zone was modelled as a random effect by including a random intercept at the zone level and allowing for a random slope on the intervention. A binary 'treatment' variable distinguished the pre-284 285 intervention period and the post-intervention period, with the control area classified as 'pre-286 intervention' throughout. Robust standard errors were used to account for autocorrelation and 287 heteroskedasticity. The zone-level and aggregate release area analyses included the pilot release area 288 of Jurujuba within zone 1.

To account for within-zone heterogeneity in *w*Mel establishment and dengue incidence, a secondary neighbourhood-level analysis was also performed in which *Wolbachia* exposure was determined by the measured *w*Mel prevalence in *Ae. aegypti* collected from each neighbourhood, and a three-month 292 moving average calculated to smooth the variability in monthly wMel prevalence, categorised into 293 quintiles of exposure. In zone 1 we excluded the neighbourhood of Jurujuba where pilot wMel releases 294 were staggered across seven sectors over a period of 16 months and wMel monitoring was initially 295 done only in small pockets of the neighbourhood where releases had already occurred, because the 296 wMel time-series during this staged release period was not representative of the whole of Jurujuba 297 neighbourhood (whereas the dengue cases data was aggregate for the whole neighbourhood). This analysis included data to March 2020 only, as no Wolbachia monitoring was possible April – June 2020 298 299 due to restrictions on movement in response to the Covid-19 pandemic. Mixed-effects negative 300 binomial regression was used to model monthly dengue case notifications by neighbourhood, in each 301 of the four release zones individually and in all zones combined, compared with the pre-specified 302 control zone. The model included population size as an offset and neighbourhood as a random effect. 303 Given the large number of zero dengue case counts (zero-inflation) at the neighbourhood level, an 304 alternative analysis using a zero-inflated negative-binomial model with robust standard errors to 305 account for clustering was considered. Model fit was not improved by accounting for zero-inflation, 306 as assessed using the Akaike Information Criterion (AIC), and was thus not used in the analyses. This 307 secondary analysis was not performed for chikungunya or Zika due to the sparsity of case data at the 308 neighbourhood level.

309

# 310 Sensitivity analyses

As a sensitivity analysis, we excluded pre-intervention observations prior to 2012 to achieve greater
 balance between pre-intervention and post-intervention period lengths while maintaining sufficient
 data to inform on pre-intervention trends.<sup>28</sup>

314

### 315 Power estimation

316 Power was estimated for the ITS analysis using 1000 simulated datasets drawn from a negative binomial distribution fitted to a ten-year time series (2007–2016) prior to Wolbachia deployment, of 317 318 monthly dengue case notifications from release and control zones in Niterói and Rio de Janeiro. The 319 simulated time series of dengue case numbers in the control zones as well as the pre- Wolbachia 320 release dengue case numbers in the treated zones were drawn directly from this model-generated 321 distribution. Post- Wolbachia release dengue case numbers in the treated zones were drawn from the 322 same model-generated distribution, modified by an additional parameter for an intervention effect of 323 Relative Risks = 0.6, 0.5, 0.4, 0.3. For each of these four 'true' effect sizes and a null effect (RR = 1),

applied to each of the 1000 simulated time series, the 'observed' effect size was calculated from a 324 325 negative binomial regression model of monthly case counts in the treated and untreated zones, as 326 described above. Post-intervention time periods of 1, 2 or 3 years were simulated, with the pre-327 intervention period fixed at 7 years. The estimated power to detect a given effect size was determined 328 as the proportion of the 1000 simulated scenarios in which a significant intervention effect (p<0.05) 329 was observed. These simulations indicate 80% power to detect a reduction in dengue incidence of 330 50% or greater after three years of post-intervention observations, and a reduction of 60% or greater 331 after two years.

332

# 333 Results

#### 334 Wolbachia establishment in Niterói

Awareness (prior knowledge of the *Wolbachia* method) ranged from 36 to 50% and acceptance (agreement with the proposed *w*Mel releases in the neighbourhood) ranged from 65 to 92%, in the public survey conducted prior to releases in Niterói. No negative media nor negative community incidents were registered, and the Community Reference Group endorsed the start of releases.

339 Heterogeneity in wMel Wolbachia establishment was observed in three of the four release zones 340 (Figure 2). In the initial release area of zone 1, Wolbachia prevalence was greater than 80% in the first 341 guarter of 2020 (up to 11 months post-release) and there was low variability across the 342 neighbourhoods. Local wMel introgression has been more variable in zones 2 and 3, with a median 343 wMel prevalence of 40 -70% among neighbourhoods during the post-release period (11 months and 9 months, respectively). In zone 4, a longer post-intervention observation period is required to 344 345 evaluate the trajectory of wMel establishment. Aedes albopictus is present throughout the city and was detected at a similar abundance in our monitoring network during and after releases (Figure S5). 346



#### 348

349 Figure 2: wMel infection prevalence in Aedes aegypti mosquitoes collected from each release 350 zone, during and after releases. Circle markers represent the aggregate wMel infection prevalence 351 in each zone in each calendar month from January 2017 to March 2020. Open circles indicate 352 months when Wolbachia releases took place in any part of that zone; filled circles are months with 353 no releases. Horizontal lines represent the median wMel infection rate among the individual 354 neighbourhoods in each zone (n=4 neighbourhoods in Zone 1; n=11 in Zone 2; n=13 in Zone 3; n=5 in 355 Zone 4). Shaded bars show the interquartile range (IQR) of wMel infection rates among the 356 individual neighbourhoods in each zone, each month. Note that in January and February 2017, the 357 only BG traps in Zone 1 were in the Jurujuba pilot release area where releases and monitoring had been ongoing throughout 2015-2016;<sup>20</sup> BG monitoring in March-April 2017 had commenced in 2/4 358 neighbourhoods and from May 2017 in all 4 Zone 1 neighbourhoods. In Zone 2, BG monitoring in 359 360 July-Sept 2017 had commenced in 7/11 neighbourhoods and from Oct 2017 in all 11 361 neighbourhoods. In Zone 3 and Zone 4, BG monitoring commenced in all neighbourhoods from Dec

363

362

364 Arboviral disease trends pre- and post-Wolbachia intervention

2017 and Oct 2019, respectively.

365 During the ten years prior to the start of scaled Wolbachia mosquito releases in Niterói in early 2017, seasonal peaks in dengue case notifications occurred each year (Figure 3A), usually in March and April 366 367 (Figure 3B). A median of 2,818 dengue cases were notified each year 2007 - 2016 (per capita incidence 368 581/100,000 population), with a minimum of 366 cases in 2014 (75/100,000) following a maximum of 369 11,618 in 2013 (2,396/100,000). In the three years following the start of phased Wolbachia releases, 370 annual city-wide dengue case notifications were 895, 1,729 and 378 in 2017, 2018 and 2019 371 respectively, and the seasonal peaks in dengue incidence occurred predominantly in the areas of 372 Niterói that had not yet received Wolbachia deployments (Figure 4).



374

Figure 3: Dengue, chikungunya and Zika time series and seasonality in Niterói. Monthly dengue (a), 375

376 chikungunya (b) and Zika (c) case notifications in Niterói from January 2007 (dengue) or January

377 2015 (chikungunya/Zika) to June 2020, and dengue (d), chikungunya (e) and Zika (f) case

378 notifications aggregated by calendar month, across the same period.



379

380 Figure 4: Dengue incidence and wMel infection prevalence in local Aedes aegypti mosquito

381 populations, by release zone. Panels A,C,E,G: Lines show the monthly incidence of dengue case 382 notifications per 100,000 population (left-hand Y axis) in Niterói release zones 1 - 4 (solid line in each 383 panel) compared with the untreated control zone (dashed line), January 2007 - June 2020. Light blue 384 shading indicates the beginning of the epidemiological monitoring period in each zone, one month 385 after initial releases were completed in each respective zone. Darker blue shading indicates the 386 aggregate wMel infection prevalence (right-hand Y axis) in each zone in each calendar month from 387 the start of the epidemiological monitoring period until March 2020 (no wMel monitoring April -

June 2020). Panels B,D,F,H show the same data but zoomed into the period from May 2017 – March
2020 and with the dengue incidence axis rescaled, to show more clearly the trends in release and
control zones in the post-intervention period.

391

392 Chikungunya surveillance commenced in January 2015. Between 44 and 533 chikungunya cases were 393 notified annually in Niterói in 2015 - 2019, with the exception of 2018 when an explosive outbreak 394 resulted in 3091 reported cases; 95% of those occurred in the six months January to June. The highest 395 per capita incidence of chikungunya during the 2018 outbreak was in the untreated control zone 396 (1,413 cases/100,000 population; Figure 5), followed by Zone 4 where Wolbachia deployments had not yet commenced (958/100,000). In Zones 1, 2, and 3 where deployments were underway and zone-397 398 level Wolbachia prevalence was between 20 – 55%, the incidence of chikungunya case notifications during the 2018 outbreak was 106/100,000, 244/100,000 and 201/100,000, respectively. 399





Figure 5: Chikungunya incidence and *w*Mel infection prevalence in local *Aedes aegypti* mosquito
populations, by release zone. Lines show the monthly incidence of chikungunya case notifications
per 100,000 population (left-hand Y axis) in Niterói release zones 1 - 4 (solid line in each panel)
compared with the untreated control zone (dashed line), January 2015 - June 2020. Light blue

shading indicates the beginning of the epidemiological monitoring period in each zone, one month
after initial releases were completed in each respective zone. Darker blue shading indicates the
aggregate wMel infection prevalence (right-hand Y axis) in each zone in each calendar month from
the start of the epidemiological monitoring period until March 2020 (no wMel monitoring April June 2020).

There were 8,247 Zika cases reported in Niterói between 2015 and June 2020, 91% (n=7,532) of which
were reported in 2015-2016 when Brazil experienced an unprecedented Zika outbreak (Figure 6).
From 2017, when phased *w*Mel deployments began in Niterói, until June 2020 a total of 715 Zika cases

414 were notified in Niterói, of which of 95 were reported from areas where *w*Mel deployments had

already occurred: 12 in zone 1, 28 in zone 2, 48 in zone 3, and 7 in zone 4.



Figure 6: Zika incidence and wMel infection prevalence in local Aedes aegypti mosquito populations, by release zone. Lines show the monthly incidence of Zika case notifications per 100,000 population (left-hand Y axis) in Niterói release zones 1 - 4 (solid line in each panel) compared with the untreated control zone (dashed line), January 2015 - June 2020. Light blue shading indicates the beginning of the epidemiological monitoring period in each zone, one month after initial releases were completed in each respective zone. Darker blue shading indicates the aggregate wMel infection prevalence (right-

- 423 hand Y axis) in each zone in each calendar month from the start of the epidemiological monitoring
- 424 period until March 2020 (no *w*Mel monitoring April June 2020).
- 425
- 426 Reduction in dengue, chikungunya and Zika incidence post-Wolbachia intervention
- 427 Using interrupted time series (ITS) analysis to account for underlying temporal trends in case incidence
- 428 and staggered implementation of the intervention, we found that *w*Mel *Wolbachia* deployments were
- 429 associated with a significant reduction in dengue incidence in each of the four release zones (Figure
- 430 6a). The magnitude of this reduction ranged from 46.0% (95%CI 21.0, 63.0) in Zone 3 to 75.9% (95%CI
- 431 62.1, 84.7) in Zone 2. Overall, Wolbachia deployments were associated with a 69.4% (95%CI 54.4,
- 432 79.4) reduction in dengue incidence in Niterói (Figure 7A; Table S1).



Figure 7: Estimated reduction in the incidence of dengue (A) chikungunya (B) and Zika (C) following *Wolbachia* deployments in Niterói, in each release zone individually and in the aggregate release
area. Point estimates (circles) and 95% confidence intervals (horizontal bars) from controlled
interrupted time series analysis of monthly dengue (Jan 2007 – June 2020), chikungunya and Zika
(Jan 2015 – June 2020) case notifications to the Brazilian national disease surveillance system.

#### 465

466 This Wolbachia intervention effect against dengue was also apparent overall, and in each zone, in the 467 neighbourhood-level analysis that considered quintiles of wMel prevalence in local Ae. aegypti 468 populations, although we found evidence of only marginal additional reductions in dengue incidence 469 at higher levels of Wolbachia beyond 20 – 40% wMel prevalence (Figure S6; Table S2). There was 470 substantial month-to-month variation in wMel quintiles within neighbourhoods (Figure S7), which was 471 reduced but not removed by taking a three-month moving average of wMel prevalence. The result 472 were little changed in the sensitivity analysis, which excluded pre-intervention observations prior to 473 2012 (Figure S8; Table S3).

A total of 897 severe dengue cases were reported in Niterói between 2007 and early 2020, 691 of which were from one of the four intervention zones and 206 from the control zone. Only three of these cases occurred in the post-intervention period, two in zone 2 and one in zone 3. The control zone has not had any severe dengue cases reported since 2016. These numbers were too sparse to be analysed using our ITS model, even when allowing for zero-inflation.

We found in ITS analysis that chikungunya incidence was also significantly reduced following *Wolbachia* deployments in Niterói as a whole (56.3% reduction in incidence; 95%Cl 15.9, 77.3) and in three of the four individual release zones (Figure 7B; Table S1). Zika incidence was reduced by 37% (95%Cl 1.5, 59.5) following *Wolbachia* deployments in Niterói as a whole, though not in individual release zones (Figure 7C; Table S1).

484

### 485 Discussion

486 Large-scale phased deployments of wMel strain Wolbachia-infected Aedes aegypti mosquitoes in 487 Niterói, Brazil during 2017 - 2019, resulted in wMel establishment in local Ae. aegypti populations at 488 an infection frequency of 33 – 90% by March 2020, when field monitoring was paused due to the 489 emergence of SARS-CoV-2 in Brazil. More than one-quarter of the total 373,000 residents of the 490 intervention area were living in neighbourhoods where local wMel prevalence was 60% or greater by 491 March 2020, predominantly in zones 1 and 2 where releases commenced earliest. In the remaining 492 intervention areas, wMel prevalence was more heterogeneous and a resumption of entomological 493 monitoring is planned in order to evaluate the long-term trajectory of wMel introgression into the 494 local Ae. aegypti population.

495 Despite this heterogeneity in Wolbachia establishment, a significant reduction in the incidence of 496 dengue, chikungunya and Zika case notifications was observed in Wolbachia-treated areas of Niterói, 497 compared with a pre-defined untreated control area. This epidemiological impact on dengue was 498 replicated across all four release zones, and in three of the four zones for chikungunya. Aggregate 499 across the whole intervention area, the wMel deployments were associated with a 69% reduction in 500 dengue incidence, a 56% reduction in chikungunya incidence and a 37% reduction in Zika incidence. 501 Given the recognised lack of evidence for efficacy of routinely available approaches to arboviral 502 disease control<sup>4</sup> based on elimination of breeding sites and insecticide-based suppression of adult 503 mosquito populations, and considering the magnitude of the historical burden of Aedes-borne disease 504 in Niterói, an intervention effect of this magnitude represents a substantial public health benefit.

505 Results from a recent cluster randomised trial of wMel-infected Ae aegypti deployments in Yogyakarta 506 Indonesia demonstrated 77% efficacy in preventing virologically confirmed dengue cases,<sup>18</sup> with 507 comparable efficacy against all four dengue virus serotypes. Previous non-randomised controlled field trials in Indonesia<sup>15</sup> and northern Australia<sup>16,17</sup> demonstrated 76% and 96% effectiveness, respectively, 508 509 in reducing the incidence of dengue cases notified to routine disease surveillance systems. In each of 510 those sites the trajectory of *w*Mel establishment was more rapid and more homogeneous across the 511 release area than observed in Niterói. In the present study, the epidemiological impact in the area of 512 Niterói where wMel introgression occurred most rapidly and homogeneously (Zone 1) was highly 513 comparable with the Indonesian studies: 77% (95%CI 64, 86). Another Wolbachia strain, wAlbB, has been successful introgressed into Ae. aegypti field populations in Kuala Lumpur, Malaysia,<sup>29</sup> although 514 515 with instability in wAlbB frequencies in some release areas after cessation of releases, which the authors attributed to immigration of wild-type mosquitoes into the small release sites (area 0.05 -516 517 0.73 km<sup>2</sup>) from surrounding untreated areas.

518 The reasons for slower and more heterogeneous wMel introgression here, compared to Indonesia and 519 Australia, are not fully understood. A likely contributing factor is that these scaled deployments have largely used adult mosquitoes released from vehicles, which does not deliver as spatially 520 521 homogeneous a deployment as occurred previously in Indonesia and Australia. In contrast, the small-522 scale pilot releases in the Jurujuba neighbourhood of Niterói in 2015 achieved rapid and sustained 523 introgression of wMel after 8 – 31 weeks of egg-based releases.<sup>20</sup> Additionally, Niterói release areas were complex urban environments with high rise areas and large informal settlements, where field 524 525 activities were frequently interrupted by security issues and where physical barriers to spread,<sup>30</sup> 526 spatial heterogeneity in mosquito abundance,<sup>31</sup> and limited mosquito dispersal<sup>32</sup> could have 527 contributed to slower wMel introgression. The wild-type egg bank in such a setting is likely to be large 528 and spatially heterogeneous, and would take time to be depleted, which is likely to have contributed 529 to the heterogeneity in wMel introgression and intermediate frequencies of Wolbachia observed in 530 our study. Regular monitoring of the wMel-Ae. aegypti broodstock has demonstrated insecticide 531 susceptibility profiles comparable with wild-type material, so a concern of increased susceptibility to 532 insecticide is not considered to be an issue here. Impaired maternal transmission by wMel -infected 533 females<sup>33,34</sup> and loss of induction of cytoplasmic incompatibility by wMel -infected males<sup>35</sup> has been observed by others at high, but field relevant, temperatures. Exposure of immature Ae. aegypti to 534 535 very high temperatures in small water containers cannot be excluded as a contributing factor to the wMel introgression patterns observed in Niteroi, especially in the more informal settlements where 536 537 the urban landscape is more vulnerable to temperature variations. Entomological monitoring in future 538 years will help clarify the long-term trajectory of wMel introgression in Niterói.

539 In large and complex urban environments, a homogeneous high level of introgression of wMel may 540 prove operationally challenging and slow to achieve, even with optimised release methods and longer 541 post-release monitoring. This poses the question of what minimum threshold of wMel prevalence is 542 needed to achieve interruption of local arbovirus transmission, and whether a dose-response 543 relationship is observed between wMel prevalence and disease reduction. Predictions from 544 mathematical models have suggested that even in conservative scenarios where scaled Wolbachia 545 deployments only reduce the reproduction number (R0) of dengue by 50%, this could lead to reductions in global case incidence of 70%,<sup>36</sup> although the impact is predicted to be highly spatially 546 547 heterogeneous, with smaller relative reductions in areas with highest transmission intensity. Our 548 findings support this prediction of epidemiological impact with imperfect wMel-mediated 549 transmission blocking, by demonstrating that measurable reductions in dengue, chikungunya and Zika 550 disease accrue even at a moderate prevalence of *w*Mel in local *Ae. aegypti* populations. A secondary 551 analysis based on measured wMel prevalence and dengue case notifications at the neighbourhood-552 level found only a marginal increase in the wMel intervention effect beyond 20 - 40% prevalence, 553 which was unexpected. This analysis also indicated substantial variability in wMel prevalence over 554 time (within neighbourhoods). This may be attributable in part to sampling variability due to small Ae. 555 *aegypti* catch numbers in some areas but may also indicate true local instability in *Wolbachia* levels. 556 When combined with people's mobility and risk of acquiring dengue outside their neighbourhood of 557 residence these factors may help explain the non-linear association between measured 558 neighbourhood-level monthly wMel infection prevalence and dengue risk. The absolute abundance 559 of wild-type Ae. aegypti, independent of wMel prevalence, is also relevant to understanding local dengue risk and could not be accounted for in our time series analyses because of a lack of baseline 560 561 (pre-intervention) mosquito collection data. We cannot exclude that incompatibility within the

562 population of *w*Mel positive and negative *Ae. aegypti* could impact overall population size and 563 contribute to the observed epidemiological outcomes. Overall, a contribution of indirect effects, 564 confounding by mosquito population size, and imperfect *w*Mel exposure measurement to the 565 observation of an epidemiological impact even at moderate *w*Mel prevalence cannot be excluded, 566 and this observation needs replication in other settings.

567 This study has some limitations. Deployments of *w*Mel-infected *Ae. aegypti* were not randomised, so 568 there is the potential for measurement of the intervention effect to be confounded by other factors 569 that differ between the release areas and the pre-defined control area. Routine disease surveillance 570 data is imperfect both in specificity (not all notified cases are true dengue/chikungunya/Zlka cases) 571 and in sensitivity (not all dengue/chikungunya/Zika cases are notified). However, the risk of these 572 factors influencing the measurement of the epidemiological endpoint here is reduced by the inclusion 573 of a parallel control with a historical dengue time series that is highly synchronous with each of the 574 release areas for ten years pre-intervention. The replication of the dengue intervention effect in each 575 of the four release zones, and for chikungunya in three zones, also mitigates the possibility that any 576 parallel change in vector control practices or healthcare seeking behaviour in intervention areas could 577 have confounded the observed result. For chikungunya and Zika, there is substantial uncertainty 578 around the point estimate of the intervention effect because case notifications for these two diseases 579 were very sparse in both release and control areas outside of a single large outbreak in 2018 and 2015-580 16,

We have demonstrated that *w*Mel introgression can be achieved across a large and complex urban environment over a period of three years to a prevalence in local *Ae. aegypti* which, while still heterogeneous, is sufficient to result in a measurable reduction in dengue, chikungunya and Zika case incidence. Ongoing entomological and epidemiological monitoring will provide additional information on the trajectory of *w*Mel establishment in areas where releases have occurred more recently, or introgression has been slower, and on the full magnitude and durability of the public health benefit.

588 1. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global 589 variation in dengue transmission intensity. Sci Transl Med 2020;12. 590 2. Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis 591 from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016;16:712-23. 592 Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: 3. 593 a systematic analysis. Lancet Infect Dis 2016;16:935-41. 594 4. Bowman LR, Donegan S, McCall PJ. Is dengue vector control deficient in effectiveness or 595 evidence?: systematic review and meta-analysis. PLoS Negl Trop Dis 2016;10:e0004551. 596 5. Sim S, Ng LC, Lindsay SW, Wilson AL. A greener vision for vector control: The example of the 597 Singapore dengue control programme. PLoS Negl Trop Dis 2020;14:e0008428. 598 6. Wilson AL, Boelaert M, Kleinschmidt I, et al. Evidence-based vector control? Improving the 599 quality of vector control trials. Trends Parasitol 2015;31:380-90. 7. 600 Aliota MT, Peinado SA, Velez ID, Osorio JE. The wMel strain of Wolbachia reduces 601 transmission of Zika virus by Aedes aegypti. Sci Rep 2016;6:28792. 602 8. Aliota MT, Walker EC, Uribe Yepes A, Velez ID, Christensen BM, Osorio JE. The wMel strain of 603 Wolbachia reduces transmission of chikungunya virus in Aedes aegypti. PLoS Negl Trop Dis 604 2016;10:e0004677. 605 Dutra HL, Rocha MN, Dias FB, Mansur SB, Caragata EP, Moreira LA. Wolbachia blocks 9. 606 currently circulating Zika virus isolates in Brazilian Aedes aegypti mosquitoes. Cell Host Microbe 607 2016;19:771-4. 608 10. Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, et al. A Wolbachia symbiont in Aedes aegypti 609 limits infection with dengue, chikungunya, and Plasmodium. Cell 2009;139:1268-78. 610 Pereira TN, Rocha MN, Sucupira PHF, Carvalho FD, Moreira LA. Wolbachia significantly 11. 611 impacts the vector competence of Aedes aegypti for Mayaro virus. Sci Rep 2018;8:6889. 612 van den Hurk AF, Hall-Mendelin S, Pyke AT, et al. Impact of Wolbachia on infection with 12. 613 chikungunya and yellow fever viruses in the mosquito vector Aedes aegypti. PLoS Negl Trop Dis 2012;6:e1892. 614 615 13. Walker T, Johnson PH, Moreira LA, et al. The wMel Wolbachia strain blocks dengue and 616 invades caged Aedes aegypti populations. Nature 2011;476:450-3. 617 Ye YH, Carrasco AM, Frentiu FD, et al. Wolbachia reduces the transmission potential of 14. 618 dengue-infected Aedes aegypti. PLoS Negl Trop Dis 2015;9:e0003894. 619 Indriani C, Tantowijoyo W, Rances E, et al. Reduced dengue incidence following deployments 15. 620 of Wolbachia-infected Aedes aegypti in Yogyakarta, Indonesia: a quasi-experimental trial using 621 controlled interrupted time series analysis. Gates Open Res 2020;4:50. 622 O'Neill SL, Ryan PA, Turley AP, et al. Scaled deployment of Wolbachia to protect the 16. 623 community from dengue and other Aedes transmitted arboviruses. Gates Open Res 2018;2:36. 624 Ryan PA, Turley AP, Wilson G, et al. Establishment of wMel Wolbachia in Aedes aegypti 17. 625 mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in 626 northern Queensland, Australia. Gates Open Res 2019;3:1547. 627 18. Utarini A, Indriani C, Ahmad RA, et al. Efficacy of Wolbachia-infected mosquito deployments 628 for dengue control. N Engl J Med 2021; In Press. 629 19. Garcia GA, Sylvestre G, Aguiar R, et al. Matching the genetics of released and local Aedes 630 *aegypti* populations is critical to assure *Wolbachia* invasion. PLoS Negl Trop Dis 2019;13:e0007023. 631 Gesto JSM, Ribeiro GS, Rocha MN, et al. Reduced competence to arboviruses following the 20. 632 sustainable invasion of Wolbachia into native Aedes aegypti from Southeastern Brazil. Sci Rep 633 2021;11:10039. 634 21. Durovni B, Saraceni V, Eppinghaus A, et al. The impact of large-scale deployment of 635 Wolbachia mosquitoes on dengue and other Aedes-borne diseases in Rio de Janeiro and Niteroi, 636 Brazil: study protocol for a controlled interrupted time series analysis using routine disease 637 surveillance data. F1000Res 2019;8:1328.

638 22. Costa GB, Smithyman R, O'Neill SL, Moreira LA. How to engage communities on a large
639 scale? Lessons from World Mosquito Program in Rio de Janeiro, Brazil [version 1; peer review: 1
640 approved, 2 approved with reservations]. Gates Open Res 2020;4.

641 23. Garcia GA, Hoffmann AA, Maciel-de-Freitas R, Villela DAM. *Aedes aegypti* insecticide
642 resistance underlies the success (and failure) of *Wolbachia* population replacement. Sci Rep
643 2020;10:63.

Rocha MN, Duarte MM, Mansur SB, et al. Pluripotency of *Wolbachia* against Arboviruses:
the case of yellow fever. Gates Open Res 2019;3:161.

646 25. Hoffmann AA, Montgomery BL, Popovici J, et al. Successful establishment of Wolbachia in
647 Aedes populations to suppress dengue transmission. Nature 2011;476:454-7.

648 26. Dar M, Giesler T, Richardson R, et al. Development of a novel ozone- and photo-stable
649 HyPer5 red fluorescent dye for array CGH and microarray gene expression analysis with consistent
650 performance irrespective of environmental conditions. BMC Biotechnol 2008;8:86.

651 27. Ministry of Health Brazil (Health Surveillance Secretariat). Guia de Vigilância em Saúde :
652 volume único.

65328.Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of654public health interventions: a tutorial. Int J Epidemiol 2017;46:348-55.

Azni WA, Hoffmann AA, NoorAfizah A, et al. Establishment of *Wolbachia* strain wAlbB in
Malaysian populations of *Aedes aegypti* for dengue control. Curr Biol 2019;29:4241-8 e5.

Schmidt TL, Filipovic I, Hoffmann AA, Rasic G. Fine-scale landscape genomics helps explain
the slow spatial spread of *Wolbachia* through the *Aedes aegypti* population in Cairns, Australia.
Heredity (Edinb) 2018;120:386-95.

Hancock PA, Ritchie SA, Koenraadt CJM, Scott TW, Hoffmann AA, Godfray HCJ. Predicting the
spatial dynamics of *Wolbachia* infections in *Aedes aegypti* arbovirus vector populations in
heterogeneous landscapes. J Appl Ecol 2019;56:1674-86.

32. Jasper M, Schmidt TL, Ahmad NW, Sinkins SP, Hoffmann AA. A genomic approach to inferring
kinship reveals limited intergenerational dispersal in the yellow fever mosquito. Mol Ecol Resour
2019;19:1254-64.

66633.Mancini MV, Ant TH, Herd CS, et al. High temperature cycles result in maternal transmission667and dengue infection differences between *Wolbachia* strains in *Aedes aegypti*. bioRxiv 2020.

84. Ross PA, Wiwatanaratanabutr I, Axford JK, White VL, Endersby-Harshman NM, Hoffmann AA.
Wolbachia infections in *Aedes aegypti* differ markedly in their response to cyclical heat stress. PLoS
Pathog 2017;13:e1006006.

671 35. Ross PA, Ritchie SA, Axford JK, Hoffmann AA. Loss of cytoplasmic incompatibility in

672 *Wolbachia*-infected *Aedes aegypti* under field conditions. PLoS Negl Trop Dis 2019;13:e0007357.

673 36. Cattarino L, Rodriguez-Barraquer I, Imai N, Cummings DAT, Ferguson NM. Mapping global

variation in dengue transmission intensity. Sci Transl Med 2020;12.

675

# 676 Acknowledgments

The authors acknowledge the municipality of Niterói for their partnership and logistical support forthis study.

679